H1 FY26 Results Announcement
| Stock | Pharmx Technologies Ltd (PHX.ASX) |
|---|---|
| Release Time | 25 Feb 2026, 8:27 a.m. |
| Price Sensitive | Yes |
Pharmx accelerates growth strategy in H1 FY26
- Total revenue of $3.9 million, up 3% on PCP
- Positive EBITDA of $0.5 million
- Increased gross margin to 84% (up 2%)
- Formed strategic alliance with Sigma as preferred EDI and growth partner
Pharmx Technologies Limited (ASX: PHX) announced its results for the half year ended 31 December 2025. The company reported total revenue of $3.9 million, representing a 3% uplift on the previous corresponding period, reflecting continued underlying momentum during a significant transition phase. Revenue growth was driven by strong performance in the Marketplace (up 24%), New Zealand (up 54%), and Gateway (up 5%) segments. Pharmx delivered positive EBITDA of $0.5 million in the period, despite increased investment in the development of the new Marketplace platform, sales and marketing, and IT infrastructure. The company also reported a 2% increase in gross margin to 84%, benefiting from a change in revenue mix and diversification of revenue streams. Pharmx's cash position remained solid, with $3.2 million in cash on hand at the end of the half year. In February 2026, Pharmx formed a strategic alliance with Sigma Healthcare Limited (SIG), appointing Pharmx as the preferred EDI (Electronic Data Interchange) service provider for Sigma's wholesale and Chemist Warehouse retail operations across Australia and New Zealand. This partnership represents a significant milestone for Pharmx, strengthening its ANZ footprint and setting the company up for further revenue diversification and growth. Looking ahead, Pharmx's key priorities include the expansion of its EDI capabilities, optimization of the Marketplace experience, and ongoing investment in its core technology infrastructure to ensure leading standards of performance, security, and scalability.
Pharmx expects continued revenue uplift following this year of transformation, driven by a growing customer base and increased platform utilization, and expansion of partnerships that reinforce its position as the leading pharmacy ordering technology provider across Australia and New Zealand.